(TheNewswire)
October 2, 2018 / TheNewswire / Vancouver, British
Columbia – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it
has appointed Dr. Sandeep Singhal to its scientific advisory team.
Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Singhal into our scientific advisory
team. He provides expertise in clinical trial design, deep analytical data support and integration. His experience is vitally
important in validating, improving robustness of our assay(s) and integrating a multi perspective of Omics as a clinical diagnostic tool. His capabilities to develop and implement custom bioinformatics
programming solutions in collaboration with labs will be an important asset for BioMark. Dr. Singhal’s contributions
will enhance our analytical bench strength as we commence commercialization of our assays which is powered by genomics,
metabolomics and big data”.
Leveraging big data from genomics, proteomics and metabolomics (Omics)
and incorporating smarter analytics to BioMark’s technology platform will improve the overall performance of the tests
significantly. Offering a unified view of these disciplines will lead to better diagnostics tools available to better manage cancer
treatment at large says”, Dr. Singhal.
About Dr. Sandeep Singhal
Dr. Singhal has over 14 years of experience as a Bioinformatician in India, Belgium, USA and Canada with a
strong background in cancer genomics, omic-data integration, modeling, algorithm development, statistical analysis and application
implementation. He has published extensively in leading scientific journals such as Nature Genetics, Journal of Clinical Oncology,
EMNO molecular medicine. He is an editorial board member of Journal of Current Trends in Translational and Research. Dr
Singhal holds Ph.D. in Bioinformatics, from Jules Bordet Institute, Universite libre de Bruxelles (ULB) Bruxelles,
Belgium and is currently a Research Scientist at Columbia University, New York where his research focus is to
understand the role of metabolism and transcriptional cross talk between epigenetic co-regulators and hormones receptor-mediated
signalling pathways in both enhancer function and promoter targeted mechanism of gene control.
Dr. Singhal completed his postdoctoral fellowship at Department of Biomedical Informatics, University of
Pittsburgh, & The Hamner Institutes for Health Sciences, North Carolina, USA and University of Alberta Canada.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect,
monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to
treatment and potentially for serial monitoring for cancer survivors.
Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation,
concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by
the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking
information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can
give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the
date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether
as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
Copyright (c) 2018 TheNewswire - All rights reserved.